Independent Nurse: Recent research indicates need for change to immunisation schedule

Polak, Monika
December 2005
GP: General Practitioner;12/2/2005, p93
The article reports that the childhood immunisation schedule looks set for a significant overhaul in the light of recent research. Professor Keith Cartwright, a member of the Joint Committee on Vaccination and Immunisation said that immunological evidence suggested additional booster doses are needed for MenC and Hib. It is not clear whether the three-dose plus booster pneumococcal conjugate vaccine schedule used in the U.S. will also be adopted by Great Britain.


Related Articles

  • PCV-10 vax cost effective vs PCV-13.  // PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p7 

    The article discusses a cost-utility analysis conducted in an Argentine healthcare system in 2011 which shows that pneumococcal 10-valent vaccine conjugate (PCV-10) is better value for money for routine child immunisation than pneumococcal 13-valent-CRM197 vaccine conjugate (PCV-13).

  • Cost a barrier for self-paid vaccination in Poland.  // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p5 

    The article discusses the results of a study which appeared in an article by M Ganczak et al. in the October 8, 2013 issue of "Vaccine," revealing that immunisation coverage for self-paid vaccines among children aged 0-5 years in Poland is largely shaped by the cost of the vaccine.

  • Recommended Childhood and Adolescent Immunization Schedule/ United States, 2003.  // MMWR: Morbidity & Mortality Weekly Report;1/31/2003, Vol. 52 Issue 4, pQ1 

    Presents information on the recommended childhood and adolescent immunization schedule in the U.S. as of January 2003. Types of vaccine administered to children and adolescents; Reasons behind the deferral of some doses of pneumococcal conjugate vaccine; Details of the National Childhood...

  • Pneumococcal vaccine gets go-ahead in child schedule. Wilkinson, Emma; Pedder, Cato // Pulse;1/8/2005, Vol. 65 Issue 1, p12 

    Reports on the inclusion of a pneumococcal vaccine to the childhood immunization schedule in Great Britain. Agreement of the Joint Committee on Vaccination and Immunisation on the pneumococcal vaccination; Difficulties in the introduction of the vaccine; Benefits of the vaccine. INSETS: The...

  • Bacterial Lipoproteins Differentially Regulate Human Primary and Memory CD4+ T and B Cell Responses to Pneumococcal Protein Antigens through Toll-Like Receptor 2. Qibo Zhang; Bagrade, Linda; Clarke, Ed; Paton, James C.; Nunez, Desmond A.; Finn, Adam // Journal of Infectious Diseases;6/1/2010, Vol. 201 Issue 11, p1753 

    Background. Bacterial lipoproteins (BLPs) are expressed across a range of bacteria and are able to activate Toll-like receptor 2 (TLR-2). BLPs enhance immune responses in naive individuals and have therefore been tested as candidate vaccine adjuvants. It is not known whether BLPs affect any...

  • Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection. Jackson, Lisa A.; Janoff, Edward N. // Clinical Infectious Diseases;11/15/2008, Vol. 47 Issue 10, p1328 

    Pneumococcal polysaccharide vaccine has been licensed for use in the United States for >30 years, and two-thirds of the elderly population in the United States have received this vaccine. Observational studies have demonstrated that pneumococcal polysaccharide vaccine reduces the risk of...

  • Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales. Henderson, Katherine L.; Muller-Pebody, Berit; Blackburn, Ruth M.; Johnson, Alan P. // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p369 

    A letter to the editor is presented about a study of the effects of immunization with pneumococcal heptavalent conjugate vaccine (PCV7) based on data on pneumococcal bacteraemia and erythromycin susceptibility tests of children in England and Wales from 2000 to 2009.

  • Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial. Roca, Anna; Hill, Philip C.; Townend, John; Egere, Uzo; Antonio, Martin; Bojang, Abdoulie; Akisanya, Abiodun; Litchfield, Teresa; Nsekpong, David E.; Oluwalana, Claire; Howie, Stephen R. C.; Greenwood, Brian; Adegbola, Richard A. // PLoS Clinical Trials;Oct2011, Vol. 8 Issue 10, Special section p1 

    Background: Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We aimed to determine the impact of PCV-7 vaccination on...

  • Pneumococcal 7-valent CRM197 vaccine conjugate.  // Reactions Weekly;Aug2014, Vol. 1516 Issue 1, p154 

    An abstract of the article "Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway," by A. Steens and colleagues is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics